Genprex Inc

NASDAQ:GNPXUnited States

Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on the development of gene-based therapies for patients with unmet medical needs. The Company's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA consists of the TUSC2 gene-expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (its ONCOPREX Nanoparticle Delivery System). The Company is also using a different gene therapy delivery system in developing its pre-clinical diabetes candidates, GPX-002 and GPX-003. Its diabetes gene therapy is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.

Contact Information

Headquarters

1601 Trinity Street Bldg. B, Suite 3.322AUSTIN, TX, United States 78712

Phone

512-537-7997

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Co-Founder

J. Rodney Varner

Chief Financial Officer

Ryan Confer

Executive Vice President, General Counsel, Chief Strategy Officer

Catherine Vaczy

Senior Vice President - Regulatory Affairs

Suzanne Thornton-Jones

Chief Manufacturing and Technology Officer

Hemant Kumar